Compare NTB & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | IRON |
|---|---|---|
| Founded | 1858 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2016 | 2020 |
| Metric | NTB | IRON |
|---|---|---|
| Price | $50.96 | $59.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $53.75 | ★ $101.67 |
| AVG Volume (30 Days) | 137.9K | ★ 582.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $4.21 | $101.57 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.86 | $30.82 |
| 52 Week High | $55.84 | $99.50 |
| Indicator | NTB | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 38.62 |
| Support Level | $48.91 | $57.81 |
| Resistance Level | $51.72 | $64.00 |
| Average True Range (ATR) | 1.06 | 2.89 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 65.82 | 16.99 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It offers banking services, comprising retail and corporate banking, and wealth management services, which consist of trust, private banking, and asset management business. The company operates through four reportable segments: Bermuda, Cayman, Channel Islands and the UK, and Other. In its Bermuda and Cayman segments, the company offers retail banking and wealth management services. In the Channel Islands and the UK segment, the company offers retail and corporate banking and wealth management services, and the Other segment includes its operations in the Bahamas, Canada, Mauritius, Singapore, and Switzerland. Maximum revenue for the company is generated from its business in Bermuda.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.